中国临床药学杂志

参考文献

[1]Gonzalez MA,Estes KS.Pharmacokinetic overview of oral second-genera-tion H1antihistamines[J].Int J Clin Pharmacol Ther,1998,36(5):292.

[2]Slater JW,Zechnich AD,Haxby DG.Second-generation antihistamines:acomparative review[J].Drugs,1999,57(1):31.

[3]Simons FE.Comparative pharmacology of H1antihistamines:clinical rele-vance[J].Am J Med,2002,113(S9A):S38.

[4]Monahan BP,Ferguson CL,Killeavy ES,et al.Torsade de pointes occur-ring in association with terfenadine use[J].JAMA,1990,264(21):2788.

[5]慕朝伟.阿司咪唑的致心律失常作用[J].中国循环杂志,1997,12(2):156.

[6]钟国平,王雪丁,张选红,等.氯雷他定在健康志愿者的药代动力学与生物等效性研究[J].中国临床药理学杂志,2002,18(2):105.

[7]张全英,冒国光.氯雷他定3种制剂生物等效性研究[J].中国新药与临床杂志,2004,23(9):599.

[8]黄永兴.新的抗组胺药氯雷他定[J].国外医药-合成药、生化药、药剂分册,1994,15:311.

[9]Clissold SP,Sorkin EM,Goa KL.Loratadine:A Preliminary review of itspharmacodynamic properties and therapeutic efficacy[J].Drugs,1989,37(1):42.

[10]Barecki ME,Casciano CN,Johnson WW,et al.In vitrocharacterizationof the inhibition profile of loratadine,desloratadine,and 3-OH-deslorata-dine for five human cytochrome P-450 enzymes[J].Drug Metab Dispos,2001,29(9):1173.

[11]刘晓琰,孙黎,费艳秋,等.国产盐酸西替利嗪的药代动力学研究[J].中国药房,2002,13(7):415.

[12]孙殿春,郑慧哲,李桂花,等.第三代H1-受体拮抗剂现状[J].中国制药信息,2001,17(11):10.

[13]孙终实.抗组胺药物的进展[J].中国新药杂志,1999,8(7):448.

[14]Markham A,Wagstaff AJ.Fexofenadine[J].Drugs,1998,55(2):269.

[15]Estelle F,Simons R.Fexofenadine-a viewpoint[J].Drugs,1998,55(2):275.

[16]Wang Z,Hamman MA,Huang SM,et al.Effect of St John’s wort onthe pharmacokinetics of fexofenadine[J].Clin Pharmacol Ther,2002,71(6):414.

[17]Banfield C,Gupta S,Marino M,et al.Grapefruit juice reduces the oralbioavailability of fexofenadine but not desloratadine[J].Clin Pharma-cokinet,2002,41(4):311.

[18]Gupta S,Banfield C,Kantesaria B,et al.Pharmacokinetic and safetyprofile of desloratadine and fexofenadine when coadministered withazithromycin:a randomized,placebo-controlled,parallel-group study[J].Clin Ther,2001,23(3):451.

[19]Banfield C,Hunt T,Reyderman L,et al.Lack of clinically relevant in-teraction between desloratadine and erythromycin[J].Clin Pharma-cokinet,2002,41(S1):29.

[20]Banfield C,Herron J,Keung A,et al.Desloratadine has no clinicallyrelevant electrocardiographic or pharmacodynamic interactions with keta-conazole[J].Clin Pharmacokinet,2002,41(S1):37.

[21]董六一,施宁,周兰兰,等.新型抗组胺药去脂氯雷他定的药理与临床[J].中国药房,2001,12(11):695.

[22]Benedetti MS,Plisnier M,Kaise J,et al.Absorption,distribution,metabolism and excretion of[14C]levocetirizine,the R enantiomer ofcetirizine,in healthy volunteers[J].Eur J Clin Pharmacol,2001,57(8):571.